

# **Company Overview**

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Woodstock, Georgia, with manufacturing operations in Jalisco, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.

Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections

Apr 4 2024, 7:30 AM EDT

Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences

Mar 28 2024, 4:01 PM EDT

Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals

Mar 27 2024, 7:30 AM EDT

# Stock Overview Investor Relations

**Symbol** SNOA T: 470-938-1011

Exchange Nasdaq ir@sonomapharm

Market Cap 2.29m Last Price \$0.1469 52-Week \$0.1159 - \$1.52

04/08/2024 03:58 PM EDT

# **Management Team**

## **Amy Trombly**

Interim Chief Executive Officer

#### **Bruce Thornton**

**Chief Operating Officer** 

#### Jerry Dvonch

Interim Chief Financial Officer

## Sonoma Pharmaceuticals, Inc.

5445 Conestoga Court Suite 150 Boulder, CO 80301

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.